New drug targets fatty liver in transplant patients
NCT ID NCT07335601
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This study tests whether resmetirom, a daily pill, can reduce liver fat in people who have had a liver transplant and developed MASH (a type of fatty liver disease). About 120 participants will be randomly assigned to receive either resmetirom or a placebo for 28 weeks. The main goal is to see if the drug lowers liver fat as measured by MRI.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Resmetirom (MGL-3196)
- What this could lead to
- If successful, this could offer a treatment to reduce liver fat and prevent further liver damage in transplant patients with MASH.
- What could go wrong
- This is an early Phase 2 trial with only 120 participants. The drug may not work better than placebo, and side effects are still being studied.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dallas Methodist
RECRUITINGDallas, Texas, 75203, United States
-
Houston Methodist Hospital
RECRUITINGHouston, Texas, 77030, United States
-
Intermountain Medical Center
RECRUITINGMurray, Utah, 84107, United States
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
Medstar Georgetown University Hospital
NOT_YET_RECRUITINGWashington D.C., District of Columbia, 20007, United States
-
NY Presbyterian- Weill Cornell Medicine
RECRUITINGNew York, New York, 10065, United States
-
Northwell Health Inc, Center for Liver Disease and Transplantation
RECRUITINGManhasset, New York, 11030, United States
-
Northwestern University
RECRUITINGChicago, Illinois, 60208, United States
-
The University of Chicago Medicine
NOT_YET_RECRUITINGChicago, Illinois, 60637, United States
-
University Health Network - Toronto General Hospital (TGH)
NOT_YET_RECRUITINGToronto, Ontario, M5G 2C4, Canada
-
University of California Los Angeles Medical Center
NOT_YET_RECRUITINGLos Angeles, California, 90095, United States
-
University of California San Diego
RECRUITINGLa Jolla, California, 92037, United States
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
-
University of Colorado
RECRUITINGAurora, Colorado, 80045, United States
-
University of Nebraska
NOT_YET_RECRUITINGOmaha, Nebraska, 68198-2000, United States
-
University of Virginia Health System
NOT_YET_RECRUITINGCharlottesville, Virginia, 22903, United States
-
Vanderbilt University Medical Center (VUMC)
RECRUITINGNashville, Tennessee, 37212, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a once-daily pill help children with fatty liver disease?
- Could a common sugar fuel liver damage?
- Can eating only during an 8-10 hour window help liver cancer patients?
- Could a quick liver scan replace needle biopsies for MASH in diabetics?
- New pill could stop liver scarring in MASH patients
- New registry tracks rezdiffra safety for moms and babies